{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:37:17Z","timestamp":1760143037796,"version":"build-2065373602"},"reference-count":49,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012940","name":"Medical Faculty of the Eberhard-Karls University of T\u00fcbingen","doi-asserted-by":"publisher","award":["2549-0-0"],"award-info":[{"award-number":["2549-0-0"]}],"id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Effective treatment options for peritoneal surface malignancies (PSMs) are scarce. Oncolytic virotherapy with recombinant vaccinia viruses might constitute a novel treatment option for PSM. We aimed to identify the most effective oncolytic vaccinia virus strain in two murine mesothelioma cell lines and the oncolytic potential in a murine model of peritoneal mesothelioma. Cell lines AB12 and AC29 were infected in vitro with vaccinia virus strains Lister (GLV-1h254), Western Reserve (GLV-0b347), and Copenhagen (GLV-4h463). The virus strain GLV-0b347 was shown most effective in vitro and was further investigated by intraperitoneal (i.p.) application to AB12 and AC29 mesothelioma-bearing mice. Feasibility, safety, and effectiveness of virotherapy were assessed by evaluating the peritoneal cancer index (PCI), virus detection in tumor tissues and ascites, virus growth curves, and comparison of overall survival. After i.p. injection of GLV-0b347, virus was detected in both tumor cells and ascites. In comparison to mock-treated mice, overall survival was significantly prolonged, ascites was less frequent and PCI values declined. However, effective treatment was only observed in animals with limited tumor burden at the time point of virus application. Nonetheless, intraperitoneal virotherapy with GLV-0b347 might constitute a novel therapeutic option for the treatment of peritoneal mesothelioma. Additional treatment modifications and combinational regimes will be investigated to further enhance treatment efficacy.<\/jats:p>","DOI":"10.3390\/cancers16020368","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T07:25:07Z","timestamp":1705303507000},"page":"368","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-8243","authenticated-orcid":false,"given":"Can","family":"Yurttas","sequence":"first","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University Hospital of T\u00fcbingen, Hoppe-Seyler-Str. 3, 72076 T\u00fcbingen, Germany"},{"name":"Virotherapy Center T\u00fcbingen (VCT), Department of Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6884-8249","authenticated-orcid":false,"given":"Julia","family":"Beil","sequence":"additional","affiliation":[{"name":"Virotherapy Center T\u00fcbingen (VCT), Department of Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"},{"name":"Department of Internal Medicine VIII, Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Berchtold","sequence":"additional","affiliation":[{"name":"Virotherapy Center T\u00fcbingen (VCT), Department of Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"},{"name":"Department of Internal Medicine VIII, Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Smirnow","sequence":"additional","affiliation":[{"name":"Virotherapy Center T\u00fcbingen (VCT), Department of Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"},{"name":"Department of Internal Medicine VIII, Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-9135","authenticated-orcid":false,"given":"Linus D.","family":"Kloker","sequence":"additional","affiliation":[{"name":"Virotherapy Center T\u00fcbingen (VCT), Department of Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"},{"name":"Department of Internal Medicine VIII, Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bence","family":"Sipos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine VIII, Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"},{"name":"BAG f\u00fcr Pathologie und Molekularpathologie, Rosenbergstra\u00dfe 12, 70176 Stuttgart, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-1317","authenticated-orcid":false,"given":"Markus W.","family":"L\u00f6ffler","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University Hospital of T\u00fcbingen, Hoppe-Seyler-Str. 3, 72076 T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Interfaculty Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, Auf der Morgenstelle 15, 72076 T\u00fcbingen, Germany"},{"name":"Department of Clinical Pharmacology, University Hospital T\u00fcbingen, Auf der Morgenstelle 8, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University Hospital of T\u00fcbingen, Hoppe-Seyler-Str. 3, 72076 T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-657X","authenticated-orcid":false,"given":"Andr\u00e9 L.","family":"Mihaljevic","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University Hospital of T\u00fcbingen, Hoppe-Seyler-Str. 3, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich M.","family":"Lauer","sequence":"additional","affiliation":[{"name":"Virotherapy Center T\u00fcbingen (VCT), Department of Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"},{"name":"Department of Internal Medicine VIII, Medical Oncology and Pneumology, University Hospital of T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site T\u00fcbingen, Otfried-M\u00fcller-Str. 10, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-7589","authenticated-orcid":false,"given":"Karolin","family":"Thiel","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, University Hospital of T\u00fcbingen, Hoppe-Seyler-Str. 3, 72076 T\u00fcbingen, Germany"},{"name":"Department of General, Visceral, and Thoracic Surgery, Oberschwaben Hospital Group, St Elisabethen-Klinikum, Elisabethenstr. 15, 88212 Ravensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ejso.2008.09.010","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma","volume":"35","author":"Yano","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jso.21177","article-title":"Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian experience","volume":"99","author":"Chua","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1080\/02656736.2018.1434902","article-title":"Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival","volume":"34","author":"Gilani","year":"2018","journal-title":"Int. J. Hyperthermia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","article-title":"Current trends in the management of malignant peritoneal mesothelioma","volume":"21","author":"Miura","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: Genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1109\u20131119.e1110","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2217\/fon-2021-0802","article-title":"Oncolytic virotherapy as promising immunotherapy against cancer: Mechanisms of resistance to oncolytic viruses","volume":"18","author":"Goradel","year":"2022","journal-title":"Future Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fonc.2017.00106","article-title":"Immune System, Friend or Foe of Oncolytic Virotherapy?","volume":"7","author":"Filley","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1245\/s10434-014-3651-4","article-title":"Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma","volume":"21","author":"Acuna","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/157016309787581084","article-title":"Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy","volume":"6","author":"Stuart","year":"2009","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kurosaki, H., Nakatake, M., Sakamoto, T., Kuwano, N., Yamane, M., Ishii, K., Fujiwara, Y., and Nakamura, T. (2021). Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD\/UPRT against Pancreatic Ductal Adenocarcinoma in Mice. Cells, 10.","DOI":"10.3390\/cells10050985"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.omto.2020.10.002","article-title":"Novel Chimeric Poxvirus CF17 Improves Survival in a Murine Model of Intraperitoneal Ovarian Cancer Metastasis","volume":"19","author":"Hammad","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.surg.2014.09.008","article-title":"Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis","volume":"157","author":"Eveno","year":"2015","journal-title":"Surgery"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omto.2020.06.021","article-title":"Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer","volume":"18","author":"Ishikawa","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jss.2019.07.032","article-title":"Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer","volume":"245","author":"Day","year":"2020","journal-title":"J. Surg. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ijc.2910520609","article-title":"Establishment of a murine model of malignant mesothelioma","volume":"52","author":"Davis","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wang, H., Chen, N.G., Minev, B.R., Zimmermann, M., Aguilar, R.J., Zhang, Q., Sturm, J.B., Fend, F., Yu, Y.A., and Cappello, J. (2013). Optical detection and virotherapy of live metastatic tumor cells in body fluids with vaccinia strains. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071105"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Carter, M.E., Hartkopf, A.D., Wagner, A., Volmer, L.L., Brucker, S.Y., Berchtold, S., Lauer, U.M., and Koch, A. (2022). A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.826302"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Koch, J., Beil, J., Berchtold, S., M\u00f6nch, D., Maa\u00df, A., Smirnow, I., Schenk, A., Carter, M.E., Kloker, L.D., and Leibold, T. (2023). Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model. Viruses, 15.","DOI":"10.3390\/v15020363"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-07-0146","article-title":"Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0008-8749(87)90038-4","article-title":"Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models","volume":"104","author":"Ottow","year":"1987","journal-title":"Cell. Immunol."},{"key":"ref_29","first-page":"012009","article-title":"Pathological And Immunological Study On Infection With Escherichia Coli In ale BALB\/c mice","volume":"1003","author":"Ali","year":"2018","journal-title":"J. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/picr.PICR_123_17","article-title":"Common pitfalls in statistical analysis: Measures of agreement","volume":"8","author":"Ranganathan","year":"2017","journal-title":"Perspect. Clin. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","article-title":"Extent of colorectal peritoneal carcinomatosis: Attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study","volume":"22","author":"Goere","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1477-7819-10-56","article-title":"Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy","volume":"10","author":"Benizri","year":"2012","journal-title":"World J. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"978394","DOI":"10.1155\/2013\/978394","article-title":"Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy","volume":"2013","author":"Yonemura","year":"2013","journal-title":"Sci. World J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2017.07.135","article-title":"Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin\u00ae) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"146","author":"Cohn","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejso.2010.10.014","article-title":"Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O","volume":"37","author":"Cavaliere","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","article-title":"The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery","volume":"156","author":"Kusamura","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","article-title":"Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival","volume":"25","author":"Verma","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2018.36.15_suppl.3531","article-title":"Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394)","volume":"36","author":"Goere","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1158\/1078-0432.CCR-17-0681","article-title":"Local Delivery of OncoVEX(mGM-CSF) Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade","volume":"23","author":"Moesta","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e006270","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J. Immunother Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.omto.2020.08.011","article-title":"High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma","volume":"18","author":"Delaunay","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1479-5876-9-164","article-title":"Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice","volume":"9","author":"Chen","year":"2011","journal-title":"J. Transl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:47:12Z","timestamp":1760104032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16020368"],"URL":"https:\/\/doi.org\/10.3390\/cancers16020368","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,1,15]]}}}